Clinical Trial Update: Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting. [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing 30 mg vs 20 mg of dexmethylphenidate extended-release in children aged 6-12 with ADHD, evaluating efficacy and safety in a laboratory …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• FOCALIN XR (DEXMETHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | Status: COMPLETED | Results posted: 2011-03-16